The most predictive cell type contexts for nominating therapeutic targets of IBD are CD4+ αβ memory T cells, enterocytes of epithelium of large intestine, T follicular helper cells, plasmablasts and myeloid dendritic cells (Fig. 5d). This evidence concerns the gene CD4 and inflammatory bowel disease.